Notably, Prg4 and Acta2 are proposed as crucial biomarkers and therapeutic targets due to their significant roles in extracellular matrix organization and cytoskeletal stability, contributing to a deeper understanding of LSS pathophysiology and potential therapeutic development. The gene discussed is PRG4; the disease is Leigh syndrome.